Cite
HARVARD Citation
Lightner, A. et al. (2022). A phase IB/IIA study of remestemcel‐L, an allogeneic bone marrow‐derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: an interim analysis. Colorectal disease. pp. 1358-1370. [Online].